ES2155702T3 - Construcciones expresivas halteroformes para la terapia genetica. - Google Patents

Construcciones expresivas halteroformes para la terapia genetica.

Info

Publication number
ES2155702T3
ES2155702T3 ES97949949T ES97949949T ES2155702T3 ES 2155702 T3 ES2155702 T3 ES 2155702T3 ES 97949949 T ES97949949 T ES 97949949T ES 97949949 T ES97949949 T ES 97949949T ES 2155702 T3 ES2155702 T3 ES 2155702T3
Authority
ES
Spain
Prior art keywords
halteroform
expressive
constructions
construct
genetic therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97949949T
Other languages
English (en)
Other versions
ES2155702T4 (es
Inventor
Burghardt Wittig
Claas Junghans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Soft Gene GmbH
Original Assignee
Soft Gene GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soft Gene GmbH filed Critical Soft Gene GmbH
Publication of ES2155702T3 publication Critical patent/ES2155702T3/es
Application granted granted Critical
Publication of ES2155702T4 publication Critical patent/ES2155702T4/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION TRATA DE UNA ESTRUCTURA DE ACIDOS NUCLEICOS QUE SE PUEDE EXPRESAR, QUE CONTIENE LA INFORMACION DE LA SECUENCIA NECESARIA PARA EXPRESAR UN GEN POR EL RNA O LA SINTESIS DE PROTEINAS. TALES ESTRUCTURAS DE EXPRESION SE PUEDEN UTILIZAR EN LA TERAPIA GENICA Y EN LA VACUNACION GENETICA, Y EVITAN MUCHOS DE LOS RIESGOS QUE VAN UNIDOS CON ESTAS ESTRUCTURAS. OTRO ASPECTO DE LA INVENCION ES LA POSIBILIDAD, MEDIANTE UN ENLACE COVALENTE DE LA ESTRUCTURA, P. E. CON PARTICULAS O PEPTIDOS, DE MEJORAR EL TRANSPORTE DE LA ESTRUCTURA EN CELULAS O TEJIDOS.
ES97949949T 1996-11-13 1997-11-13 Construcciones expresivas halteroformes para la terapia genetica. Expired - Lifetime ES2155702T4 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19648625A DE19648625A1 (de) 1996-11-13 1996-11-13 Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer

Publications (2)

Publication Number Publication Date
ES2155702T3 true ES2155702T3 (es) 2001-05-16
ES2155702T4 ES2155702T4 (es) 2002-12-16

Family

ID=7812619

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97949949T Expired - Lifetime ES2155702T4 (es) 1996-11-13 1997-11-13 Construcciones expresivas halteroformes para la terapia genetica.

Country Status (8)

Country Link
US (2) US6451593B1 (es)
EP (1) EP0941318B9 (es)
AT (1) ATE198767T1 (es)
AU (1) AU5308698A (es)
DE (3) DE19648625A1 (es)
DK (1) DK0941318T5 (es)
ES (1) ES2155702T4 (es)
WO (1) WO1998021322A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19648625A1 (de) * 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
DE19753182A1 (de) * 1997-11-21 1999-07-29 Claas Junghans Topologisch fixierte matrixgebundene Nukleinsäure
DE19826758C1 (de) * 1998-06-15 1999-10-21 Soft Gene Gmbh Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte
EP1165813A2 (en) * 1999-03-24 2002-01-02 The Board Of Regents, The University Of Texas System Linear and circular expression elements
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
GB9924981D0 (en) * 1999-10-21 1999-12-22 Univ Manchester Gene therapy
DE10025920A1 (de) * 2000-05-27 2001-12-06 Mologen Forschungs Entwicklung Verfahren und Mittel zur Behandlung von Immunreaktionen am Auge
DE10119005A1 (de) * 2001-04-18 2002-10-24 Roche Diagnostics Gmbh Verfahren zur Proteinexpression ausgehend von stabilisierter linearer kurzer DNA in zellfreien in vitro-Transkription/Translations-Systemen mit Exonuklease-haltigen Lysaten oder in einem zellulären System enthaltend Exonukleasen
WO2002100317A2 (en) * 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
DK1432439T3 (da) * 2001-10-02 2006-04-03 Mologen Ag Middel til forbedring af immunsvaret
AU2002349278A1 (en) * 2001-10-02 2003-04-22 Mologen Ag Dna-expression construct for treatment of infections with leishmaniasis
US20150050317A1 (en) * 2013-08-19 2015-02-19 Mologen Ag Means for Eliciting an Immune Response and a Method Therefor
EP1507540A4 (en) * 2001-10-10 2006-12-06 Centocor Inc NUCLEIC ACID VACCINES USING NUCLEIC ACIDS ENCODING A TUMOR ANTIGEN AND A NUCLEIC ACID ENCODING A CYTOKINE ADJUVANT
ITMN20020013A1 (it) 2002-04-04 2003-10-06 Amfag Spa Doccia estraibile da cucina
DE10393455D2 (de) * 2002-07-19 2005-06-16 Mologen Ag DNA-Expressionskonstrukt zur multiplen Genexpression
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
EP1553977B1 (de) 2002-09-23 2006-08-09 Mologen AG Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
AU2003222173A1 (en) * 2003-04-01 2004-11-23 Patrick J. Branigan Nucleic acid compositions and methods for use
EP1631672B1 (de) * 2003-06-10 2006-09-20 Mologen AG Zirkuläres expressionskonstrukt für gentherapeutische anwendungen
US20050137156A1 (en) * 2003-08-09 2005-06-23 Johnston Stephen A. Methods and compositions for generating an immune response
EP1615663B1 (de) 2003-10-24 2007-12-26 Mologen AG Mittel zur behandlung von infektionen mit leishmanien
DK1699480T3 (da) 2003-12-30 2011-10-10 Mologen Ag Allogent terapeutisk tumormiddel
US7613295B2 (en) * 2004-02-18 2009-11-03 Harris Corporation Cryptographic device and associated methods
CN1918293A (zh) 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
WO2005116223A1 (de) * 2004-05-28 2005-12-08 Mologen Ag Herstellungsverfahren geeigneter dna-konstrukte zur spezifischen hemmung der genexpression durch rna-interferenz
ES2364663T3 (es) * 2004-08-12 2011-09-08 Cedars-Sinai Medical Center Terapia génica combinada para el tratamiento de gliomas macroscópicos.
KR20080082956A (ko) 2005-09-15 2008-09-12 노보솜 아게 양쪽성 리포솜의 개선 또는 양쪽성 리포솜에 관련된 개선
BRPI0618907A2 (pt) * 2005-11-25 2012-04-17 Mologen Ag c0nstructo de expressão de dna, método de produção de vetores, kit para produção de vetores e para produção de constructo de expressão
CA2665783C (en) 2006-10-13 2015-12-15 Novosom Ag Improvements in or relating to amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
WO2008095027A2 (en) * 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
DE102007029471A1 (de) 2007-06-20 2008-12-24 Novosom Ag Neue fakultativ kationische Sterole
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
CA2765694C (en) 2009-07-09 2021-05-18 Marina Biotech, Inc. Amphoteric liposomes comprising imino lipids
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
GB2483462A (en) * 2010-09-08 2012-03-14 Mologen Ag Use of a dumbbell-shaped DNA construct for the treatment of cancer through jet-injection administration
GB201021873D0 (en) * 2010-12-23 2011-02-02 Mologen Ag DNA expression construct
BR112014001699A2 (pt) 2011-07-25 2017-06-13 Oxford Nanopore Tech Ltd método para sequenciar de um polinucleotídeo alvo de filamento duplo, kit, métodos para preparar um polinucleotídeo alvo de filamento duplo para sequenciamento e para sequenciar um polinucleotídeo alvo de filamento duplo, e, aparelho
WO2013034687A1 (en) 2011-09-09 2013-03-14 Universität Bern Verwaltungsdirektion Avibacterium paragallinarum rtx toxin
EP2875154B1 (en) 2012-07-19 2017-08-23 Oxford Nanopore Technologies Limited SSB method for characterising a nucleic acid
AU2014224432B2 (en) 2013-03-08 2019-10-24 Oxford Nanopore Technologies Limited Enzyme stalling method
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
GB201418159D0 (en) * 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
US10612077B2 (en) * 2014-10-23 2020-04-07 Ricardo Mancebo Reagents and methods for isothermal chain reaction
LT3240801T (lt) 2014-12-31 2021-02-25 Checkmate Pharmaceuticals, Inc. Kombinuota navikų imunoterapija
GB201509578D0 (en) * 2015-06-03 2015-07-15 Univ Singapore Vectors
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
MX2020010410A (es) 2018-04-09 2021-01-15 Checkmate Pharmaceuticals Empaquetado de oligonucleotidos en particulas similares a virus.
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
WO2019226650A1 (en) 2018-05-23 2019-11-28 Modernatx, Inc. Delivery of dna
EP3854419A1 (en) * 2020-01-24 2021-07-28 Univerzita Karlova, Lekarska fakulta v Plzni Dna conjugate and method of transformation of genes into cells
GB202014772D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Nucleic acid construct
WO2022240806A1 (en) 2021-05-11 2022-11-17 Modernatx, Inc. Non-viral delivery of dna for prolonged polypeptide expression in vivo
GB202204112D0 (en) 2022-03-23 2022-05-04 Lightbio Ltd Linear construct

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3221683B2 (ja) 1994-01-21 2001-10-22 パウダージェクト ヴァクシンズ， インコーポレイテッド ガス駆動型遺伝子搬入装置
DE4416784A1 (de) * 1994-05-09 1995-11-30 Soft Gene Gmbh Methode zur Anreicherung von Zellen, die durch ballistischen Transfer modifiziert wurden
FR2731014B1 (fr) 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
DE19510696A1 (de) 1995-03-14 1996-09-19 Soft Gene Gmbh Vorrichtung zur Druckverteilung im Kopfstück einer Apparatur zum ballistischen Transfer von Zellen
FR2732971B1 (fr) * 1995-04-13 1997-07-04 Genset Sa Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere
DE19648625A1 (de) * 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer

Also Published As

Publication number Publication date
DE19648625A1 (de) 1998-05-14
DE59702936D1 (de) 2001-02-22
EP0941318B1 (de) 2001-01-17
ATE198767T1 (de) 2001-02-15
DE19781276D2 (de) 1999-09-30
EP0941318B9 (de) 2001-12-19
DK0941318T3 (da) 2001-05-21
DK0941318T5 (da) 2002-02-18
US6451593B1 (en) 2002-09-17
US20030054392A1 (en) 2003-03-20
WO1998021322A1 (de) 1998-05-22
AU5308698A (en) 1998-06-03
HK1024714A1 (en) 2000-10-20
EP0941318A1 (de) 1999-09-15
ES2155702T4 (es) 2002-12-16
US7074772B2 (en) 2006-07-11

Similar Documents

Publication Publication Date Title
ES2155702T3 (es) Construcciones expresivas halteroformes para la terapia genetica.
FR19C1020I1 (fr) Nouvelles molecules b7-4 et leurs utilisations
AU7599500A (en) Novel gl50 molecules and uses therefor
WO2001072976A3 (en) 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
WO2001073028A3 (en) A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
MXPA04004561A (es) Distribuidor de aire para sistema de biolixiviacion.
WO2003012121A3 (en) Collagen xxii, a novel human collagen and uses thereof
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof
DE60137222D1 (de) Humanes trp-ähnliches kalziumkanalprotein-2 tlcc-2
WO2002006485A3 (en) 47885, a novel human ubiquitin-activating enzyme and uses therefor
WO2001075076A3 (en) 33167, a novel human hydrolase and uses therefor
ATE346926T1 (de) Menschliche twik-8 moleküle und ihre verwendung
WO2002020739A3 (en) Human matrix metalloproteinase
WO2003020912A3 (en) Novel clark protein and nucleic acid molecules and uses therefor
WO2002024898A3 (en) 47647, a human lipase and uses therefor
MXPA03002557A (es) Interactores de canales del potasio y sus usos.
WO2002029042A3 (en) 48120, 23479, and 46689, novel human hydrolases and uses thereof
WO2001079293A3 (en) Human cadherin molecules and uses therefor
AU2001285204A1 (en) Atcr-1, a human acyltransferase and uses thereof
WO2002066670A3 (en) 46798, a human matrix metalloproteinase and uses therefor
WO2002029037A3 (en) 57800, a novel human cadherin and uses therefor
WO2002062948A3 (en) 25828, a novel human aminopeptidase and uses therefor
WO2001090322A3 (en) 32244, a novel human amp-binding enzyme and uses thereof

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 941318

Country of ref document: ES